公开(公告)号：US20190195862A1

公开(公告)日：2019-06-27

申请号：US16229176

申请日：2018-12-21

申请人： THE BROAD INSTITUTE, INC. ,  DANA-FARBERCANCER INSTITUTE, INC

发明人： DAVID K. THOMAS ,  TODD R. GOLUB

IPC分类号： G01N33/50 ,  A61P3/00 ,  A61K39/395 ,  G01N33/53 ,  A61K38/00 ,  C07K16/28 ,  A61K31/506 ,  A61K31/454 ,  A61K31/164 ,  A61K31/05 ,  A61K45/06 ,  A61K38/17 ,  G01N33/68 ,  A61K31/519 ,  A61K31/7068

CPC分类号： G01N33/5061 ,  A61K31/05 ,  A61K31/164 ,  A61K31/454 ,  A61K31/506 ,  A61K31/519 ,  A61K31/7068 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P3/00 ,  C07K16/2803 ,  G01N33/5067 ,  G01N33/53 ,  G01N33/5308 ,  G01N33/6893 ,  G01N2800/04 ,  G01N2800/52 ,  G01N2800/60 ,  A61K2300/00

摘要： The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.

公开(公告)号：US20160305934A1

公开(公告)日：2016-10-20

申请号：US15101865

申请日：2014-12-04

申请人： THE BROAD INSTITUTE, INC. ,  DANA-FARBER CANCER INSTITUTE, INC.

发明人： DAVID K. THOMAS ,  TODD R. GOLUB

IPC分类号： G01N33/50 ,  A61K31/519 ,  G01N33/68 ,  A61K39/395 ,  A61K31/7068

CPC分类号： G01N33/5061 ,  A61K31/05 ,  A61K31/164 ,  A61K31/454 ,  A61K31/506 ,  A61K31/519 ,  A61K31/7068 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P3/00 ,  C07K16/2803 ,  G01N33/5067 ,  G01N33/53 ,  G01N33/5308 ,  G01N33/6893 ,  G01N2800/04 ,  G01N2800/52 ,  G01N2800/60 ,  A61K2300/00

摘要： The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.

摘要翻译： 本发明提供了指示预恶病质，组合物和方法的标志物，用于鉴定具有指示恶病前恶病的分子标记的患者; 一种培养体系，其体外再现细胞中的糖皮质过程，其有助于筛选和鉴定用于将恶病质恶化至难治性恶病质的进展的缓解（减缓，减少，逆转或预防）的治疗剂; 以及使用本发明的培养系统鉴定的治疗剂。

公开(公告)号：US20180362647A1

公开(公告)日：2018-12-20

申请号：US16061652

申请日：2016-12-13

申请人： THE BROAD INSTITUTE, INC. ,  DANA-FARBER CANCER INSTITUTE, INC.

发明人： DAVID K. THOMAS ,  TODD R. GOLUB

IPC分类号： C07K16/28 ,  A61P9/04 ,  A61P9/10

摘要： The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.